Results 81 to 90 of about 52,641 (262)

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon, Wendy Wang, Faye L. Norby, Rob F. Walker, Shalini Kulasingam, Lisa S. Chow, Joel F. Farley, Pamela L. Lutsey   +7 more
wiley   +1 more source

GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance

Chronic Diseases and Translational Medicine, EarlyView.
Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig, Jason Ta, Sophie Jones, Emily Scott, Khalid Sofi, Frances Osler, Marije Jansen, Puneet Chhabra   +7 more
wiley   +1 more source

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug–Drug Interactions for Orforglipron, a Small Molecule Glucagon‐Like Peptide‐1 Receptor Agonist

Clinical Pharmacology &Therapeutics, EarlyView.
Orforglipron is an orally administered, small‐molecule glucagon‐like peptide‐1 receptor agonist in clinical development for the treatment of type 2 diabetes and obesity. Orforglipron is a substrate of CYP3A4, organic anion transporting polypeptides (OATPs) 1B/1B3, and P‐glycoprotein (P‐gp); however, precipitants commonly used to define these mechanisms
Bridget L. Morse, David E. Coutant, Xiaosu Ma, Sohini Raha, Keerthan Aithal, Clare Nicoll, Luc R. A. Rougée, Shobha Bhattachar   +7 more
wiley   +1 more source

Estimation of insulin sensitivity from continuous glucose monitoring and insulin pump data in type 1 diabetes [PDF]

, 2012
Diabetes mellitus is a disease characterized by chronic hyperglycemia either due to a lack of secretion of the hormone insulin (Type 1 Diabetes Mellitus, T1DM) or due to impaired action of this hormone (Type 2 Diabetes Mellitus, T2DM).
Ronca, Gabriele
core  

Effects of Fomepizole on Acetaminophen Oxidative Metabolism: A Randomized, Crossover Study in Human Volunteers

Clinical Pharmacology &Therapeutics, EarlyView.
Acetaminophen overdose can cause liver injury. Hepatotoxicity results from N‐acetyl‐p‐benzoquinone imine (NAPQI), generated via cytochrome P450‐2E1 (CYP2E1). Acetylcysteine is the mainstay of treatment, but efficacy may be reduced with delayed administration or large ingestions.
Sidharth Anand, Nicholas A. Buckley, Paul Stathakis, Laura James, Larry Parker, Mitchell R. McGill, Angela L Chiew   +6 more
wiley   +1 more source

Characterization of the Immune Response after Oral Cholera Vaccination (OCV) and Effects of Mycophenolate Mofetil on Priming of this Immune Response—A Randomized, Placebo‐Controlled Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Mycophenolate mofetil (MMF) is an immunosuppressive drug widely used by solid organ transplant recipients. Although it is known that MMF suppresses immune responses, its exact effects on specific vaccinations have not been investigated yet. Mucosal vaccinations are increasingly used, such as a cholera vaccination consisting of two oral immunizations ...
Boukje C. Eveleens Maarse, Aliede E. in 't Veld, Hendrika W. Grievink, Manon A.A. Jansen, Matthijs Moerland   +4 more
wiley   +1 more source

Investigating Perceptions of the Eating Disorder Examination‐Questionnaire Among Undergraduate Students: A Qualitative Approach

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Quantitative methods that have evaluated the Eating Disorder Examination Questionnaire (EDE‐Q) have found consistent evidence that the original four‐factor structure does not replicate across diverse samples and genders. Emerging evidence in the broader psychology literature shows that qualitative methods can provide nuanced insight ...
Katarina L. Huellemann, Safia Ouédraogo, Janet A. Lydecker, Sarah E. Racine   +3 more
wiley   +1 more source

Delayed Gastric Emptying in Parkinson\u27s Disease [PDF]

Gastrointestinal symptoms are evident in all stages of Parkinson\u27s disease (PD). Most of the gastrointestinal abnormalities associated with PD are attributable to impaired motility. At the level of the stomach, this results in delayed gastric emptying.
Marrinan S, Emmanuel AV, Burn DJ
core  

Experiencing Extreme Hunger in Anorexia Nervosa Recovery: A Qualitative Analysis of Reddit Narratives

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Recovery from anorexia nervosa involves psychological and social adjustments that extend beyond weight restoration. Online forums increasingly serve as spaces where recovery experiences are openly shared, including accounts of “extreme hunger” during refeeding—a phenomenon that has not been reported in the clinical literature.
Léonie Langanay, Charlotte Meric, Margot Trimbur, Joël Charbit, Maxime Bubrovszky, Marion Hendrickx, Antoine Lamer   +6 more
wiley   +1 more source